Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Peer-Reviewed|December 23, 2020

Evidence-Based Oncology

  • January 2021
  • Volume 27
  • Issue 1

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

eAPPENDIX Clinical and Economic Burden of Intravenous Paclitaxel

Articles in this issue

over 5 years ago

ASH 2020: Clinical Updates

over 5 years ago

ASH 2020: COVID-19 and Hematology

over 5 years ago

ASH 2020: CAR T-Cell Therapy Updates

over 5 years ago

ASH 2020: The Next Wave

over 5 years ago

2020 SABCS: Topics in Precision Oncology

over 5 years ago

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

over 5 years ago

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

over 5 years ago

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

over 5 years ago

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Related Content